INC Research (NASDAQ: INCR) has recently received a number of price target changes and ratings updates:

  • 12/7/2017 – INC Research was upgraded by analysts at BidaskClub from a “sell” rating to a “hold” rating.
  • 12/1/2017 – INC Research had its price target lowered by analysts at SunTrust Banks, Inc. to $50.00. They now have a “buy” rating on the stock.
  • 12/1/2017 – INC Research was given a new $41.00 price target on by analysts at Mizuho. They now have a “neutral” rating on the stock.
  • 11/16/2017 – INC Research was downgraded by analysts at Zacks Investment Research from a “hold” rating to a “strong sell” rating. According to Zacks, “INC Research Holdings, Inc. is a global contract research organization. It provides the full range of Phase I to Phase IV clinical development services for the biopharmaceutical and medical device industries. Its services include clinical trial management services comprising patient recruitment and retention, project management, clinical monitoring, drug safety/pharmacovigilance, medical affairs, quality assurance, regulatory and medical writing, and functional service; and data services consisting of clinical data management, electronic data capture, and biostatistics. INC Research Holdings, Inc. is headquartered in Raleigh, North Carolina. “
  • 11/16/2017 – INC Research was given a new $46.00 price target on by analysts at Robert W. Baird. They now have a “buy” rating on the stock.
  • 11/14/2017 – INC Research had its price target lowered by analysts at Credit Suisse Group AG from $68.00 to $54.00. They now have an “outperform” rating on the stock.
  • 11/13/2017 – INC Research had its “market perform” rating reaffirmed by analysts at KeyCorp. They now have a $46.00 price target on the stock, down previously from $68.00.
  • 11/10/2017 – INC Research had its “buy” rating reaffirmed by analysts at Jefferies Group LLC. They now have a $55.00 price target on the stock.
  • 11/10/2017 – INC Research was downgraded by analysts at Robert W. Baird to an “outperform” rating. They now have a $46.00 price target on the stock, down previously from $67.00.
  • 11/6/2017 – INC Research was upgraded by analysts at TheStreet from a “c” rating to a “b-” rating.
  • 10/11/2017 – INC Research is now covered by analysts at Credit Suisse Group AG. They set an “outperform” rating and a $68.00 price target on the stock.
  • 10/9/2017 – INC Research was upgraded by analysts at Jefferies Group LLC from a “hold” rating to a “buy” rating. They now have a $69.00 price target on the stock, up previously from $62.50.
  • 10/9/2017 – INC Research had its “buy” rating reaffirmed by analysts at Robert W. Baird. They now have a $67.00 price target on the stock.

Shares of INC Research Holdings, Inc. (NASDAQ INCR) traded down $0.20 during trading on Thursday, hitting $37.95. The company had a trading volume of 1,959,100 shares, compared to its average volume of 929,123. The company has a debt-to-equity ratio of 0.99, a current ratio of 1.27 and a quick ratio of 1.27. INC Research Holdings, Inc. has a 1 year low of $33.60 and a 1 year high of $61.10. The firm has a market cap of $3,980.76, a P/E ratio of 17.50, a P/E/G ratio of 1.20 and a beta of 1.08.

INC Research (NASDAQ:INCR) last issued its quarterly earnings data on Thursday, November 9th. The company reported $0.54 earnings per share (EPS) for the quarter, missing the Thomson Reuters’ consensus estimate of $0.63 by ($0.09). The company had revenue of $592.21 million for the quarter, compared to analyst estimates of $604.95 million. INC Research had a positive return on equity of 14.42% and a negative net margin of 4.29%. The company’s revenue for the quarter was up 128.2% on a year-over-year basis. During the same quarter in the prior year, the firm earned $0.64 earnings per share. equities research analysts expect that INC Research Holdings, Inc. will post 2.15 earnings per share for the current fiscal year.

In other news, CAO Christopher L. Gaenzle sold 4,682 shares of the business’s stock in a transaction on Monday, September 18th. The shares were sold at an average price of $54.56, for a total transaction of $255,449.92. Following the completion of the sale, the chief accounting officer now directly owns 60,579 shares of the company’s stock, valued at approximately $3,305,190.24. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. Also, CFO Gregory S. Rush sold 9,703 shares of the business’s stock in a transaction on Monday, September 18th. The shares were sold at an average price of $54.48, for a total transaction of $528,619.44. Following the sale, the chief financial officer now directly owns 78,593 shares of the company’s stock, valued at $4,281,746.64. The disclosure for this sale can be found here. Insiders sold a total of 16,733 shares of company stock valued at $912,270 over the last ninety days. 0.24% of the stock is owned by corporate insiders.

INC Research Holdings, Inc is a global contract research organization (CRO). The Company focuses on Phase I to Phase IV clinical development services for the biopharmaceutical and medical device industries. The Company operates through two segments: Clinical Development Services and Phase I Services.

Receive News & Ratings for INC Research Holdings Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for INC Research Holdings Inc and related companies with MarketBeat.com's FREE daily email newsletter.